Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Harris, L. Jeff; Patel, Kruti; Martin, Michael

doi:10.3390/ijms21228553

Cited by 22 publications

(20 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Targeting the CD79b pan-B marker is ideal in patients who may later need CD19-targeted CAR-T cell therapy because it will not develop resistance to CD19 regimens (35).…”

Section: Polatuzumab Vedotinmentioning

confidence: 99%

“…This therapeutic agent detects the CD79b protein from the B cell receptor complex and after binding to it, inhibits tubulin polymerization by entering the cytotoxic payload of MMAE drug into B-cell, leading to the death of the target cell. Targeting the CD79b pan-B marker is ideal in patients who may later need CD19-targeted CAR-T cell therapy because it will not develop resistance to CD19 regimens ( 35 ).…”

Section: Current Immunotherapeutic Approaches For Nhl’smentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

et al. 2021

View full text Add to dashboard Cite

Non-Hodgkin’s lymphoma (NHL) is a cancer that starts in the lymphatic system. In NHL, the important part of the immune system, a type of white blood cells called lymphocytes become cancerous. NHL subtypes include marginal zone lymphoma, small lymphocytic lymphoma, follicular lymphoma (FL), and lymphoplasmacytic lymphoma. The disease can emerge in either aggressive or indolent form. 5-year survival duration after diagnosis is poor among patients with aggressive/relapsing form of NHL. Therefore, it is necessary to understand the molecular mechanisms of pathogenesis involved in NHL establishment and progression. In the next step, we can develop innovative therapies for NHL based on our knowledge in signaling pathways, surface antigens, and tumor milieu of NHL. In the recent few decades, several treatment solutions of NHL mainly based on targeted/directed therapies have been evaluated. These approaches include B-cell receptor (BCR) signaling inhibitors, immunomodulatory agents, monoclonal antibodies (mAbs), epigenetic modulators, Bcl-2 inhibitors, checkpoint inhibitors, and T-cell therapy. In recent years, methods based on T cell immunotherapy have been considered as a novel promising anti-cancer strategy in the treatment of various types of cancers, and particularly in blood cancers. These methods could significantly increase the capacity of the immune system to induce durable anti-cancer responses in patients with chemotherapy-resistant lymphoma. One of the promising therapy methods involved in the triumph of immunotherapy is the chimeric antigen receptor (CAR) T cells with dramatically improved killing activity against tumor cells. The CAR-T cell-based anti-cancer therapy targeting a pan–B-cell marker, CD19 is recently approved by the US Food and Drug Administration (FDA) for the treatment of chemotherapy-resistant B-cell NHL. In this review, we will discuss the structure, molecular mechanisms, results of clinical trials, and the toxicity of CAR-T cell-based therapies. Also, we will criticize the clinical aspects, the treatment considerations, and the challenges and possible drawbacks of the application of CAR-T cells in the treatment of NHL.

show abstract

“…Targeting the CD79b pan-B marker is ideal in patients who may later need CD19-targeted CAR-T cell therapy because it will not develop resistance to CD19 regimens (35).…”

Section: Polatuzumab Vedotinmentioning

confidence: 99%

Section: Current Immunotherapeutic Approaches For Nhl’smentioning

confidence: 99%

RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition, berberine can improve the efficiency of the anti-CD47 antibody and rituximab on cell phagocytosis ( Chao et al, 2010 ; Weiskopf et al, 2016 ; Schürch et al, 2019 ). Berberine is beneficial in immunochemotherapy based on rituximab in combination with anti-CD47 in diffuse large B-cell lymphoma ( Harris et al, 2020 ; Ren et al, 2021 ).…”

Section: Antitumor Effects and Corresponding Mechanismsmentioning

confidence: 99%

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Chen

Liang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is a serious disease with an increasing number of reported cases and high mortality worldwide. Gastrointestinal cancer defines a group of cancers in the digestive system, e.g., liver cancer, colorectal cancer, and gastric cancer. Coptidis Rhizoma (C. Rhizoma; Huanglian, in Chinese) is a classical Chinese medicinal botanical drug for the treatment of gastrointestinal disorders and has been shown to have a wide variety of pharmacological activity, including antifungal, antivirus, anticancer, antidiabetic, hypoglycemic, and cardioprotective effects. Recent studies on C. Rhizoma present significant progress on its anticancer effects and the corresponding mechanisms as well as its clinical applications. Herein, keywords related to C. Rhizoma, cancer, gastrointestinal cancer, and omics were searched in PubMed and the Web of Science databases, and more than three hundred recent publications were reviewed and discussed. C. Rhizoma extract along with its main components, berberine, palmatine, coptisine, magnoflorine, jatrorrhizine, epiberberine, oxyepiberberine, oxyberberine, dihydroberberine, columbamine, limonin, and derivatives, are reviewed. We describe novel and classic anticancer mechanisms from various perspectives of pharmacology, pharmaceutical chemistry, and pharmaceutics. Researchers have transformed the chemical structures and drug delivery systems of these components to obtain better efficacy and bioavailability of C. Rhizoma. Furthermore, C. Rhizoma in combination with other drugs and their clinical application are also summarized. Taken together, C. Rhizoma has broad prospects as a potential adjuvant candidate against cancers, making it reasonable to conduct additional preclinical studies and clinical trials in gastrointestinal cancer in the future.

show abstract

“…Several regimens approved globally and under consideration in Japan may provide a snapshot into the future of the changing treatment landscape [ 36–39 ]. The increased availability of future regimens that can be applicable in outpatient settings may shift the treatment landscape of care more toward outpatient settings in Japan as well, to potentially reduce inpatient costs [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

“…The results of this study serve as an initial foundation for future research on superior therapies to meet the unmet needs of patients with r/r DLBCL, who are subjected to a limited range of effective therapies. The future introduction of novel therapies currently available in other parts of the world [ 40 ] may pave the way to better care for r/r DLBCL patients in Japan.…”

Section: Discussionmentioning

confidence: 99%

Economic Burden in Treated Japanese Patients with Relapsed/Refractory Large B-Cell Lymphoma

Tsutsué

Makita

Yi³

et al. 2021

Future Oncol.

View full text Add to dashboard Cite

Aim: To understand the economic burden of relapsed and refractory large B-cell lymphoma patients in Japan treated with salvage chemotherapy. Patients & methods: Patients who received systemic therapy after first-line treatment were analyzed to assess its associated cost and resource use using a retrospective claims database. The impact of COVID-19 was assessed separately. Results & conclusion: This study identified 2927 and 1085 patients in the second- (2L) and third-line (3L) cohorts. The median ages for the 2L and 3L cohorts were 71 and 70 years, respectively, with Charlson Comorbidity Score of 3. A majority of the patients had limited stem cell transplant due to advanced age. Median lengths of inpatient stay for the 2L and 3L cohorts were 118 and 116 days, respectively. The majority of costs were attributed to inpatient costs, and limited COVID-19 impact was observed in this study.

show abstract

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cited by 22 publications

References 58 publications

RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Economic Burden in Treated Japanese Patients with Relapsed/Refractory Large B-Cell Lymphoma

Contact Info

Product

Resources

About